Ruxolitinib

證據等級: L5

預測適應症: 10 個

Ruxolitinib: From Myelofibrosis/GvHD to Infection-Associated Hemophagocytic Syndrome

Note on scope: This evidence pack lists 10 TxGNN-predicted indications for ruxolitinib. Nine of them (uterine corpus PEComa, benign PEComa, lymphangiomyoma, LAM, liposarcoma, familial rhabdoid tumor, lung PEComa, ovarian myxoid liposarcoma, malignancy-associated HLH) have TxGNN scores >99% but zero supporting clinical trials or literature (Evidence Level L5, recommendation "Hold"). Only rank 9 — "hemophagocytic syndrome associated with an infection" — has actual clinical trial and literature support, so this report focuses on that candidate as the actionable one.

One-Sentence Summary

Ruxolitinib is a JAK1/2 inhibitor internationally approved for myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease (GvHD), though it currently holds no New Zealand market authorization in this dataset. The TxGNN model predicts it may be effective for infection-associated hemophagocytic syndrome (HLH), and this is the one candidate among ten backed by real-world data: 2 clinical trials and 20 publications, including several cohort studies of ruxolitinib used as salvage or first-line HLH therapy.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (0 New Zealand licenses on file); internationally, ruxolitinib is approved for myelofibrosis, polycythemia vera, and steroid-refractory acute/chronic GvHD
Predicted New Indication	Hemophagocytic syndrome associated with an infection
TxGNN Prediction Score	99.32% (graph rank 5646)
Evidence Level	L3 (observational cohort studies; no completed Phase 2/3 RCT yet — the one Phase 3 trial is status UNKNOWN, and the Phase 1 trial has not started recruiting)
New Zealand Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed structured MOA data was not populated in this evidence pack (flagged as a High-severity data gap). Based on established pharmacology, ruxolitinib is a small-molecule inhibitor of Janus kinase 1 and 2 (JAK1/2), blocking downstream JAK-STAT signaling triggered by pro-inflammatory cytokines such as IFN-γ, IL-6, and IL-2.

Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory cytokine-storm syndrome — in infection-triggered HLH, excessive IFN-γ and IL-6 signaling drives macrophage/T-cell activation and multi-organ damage. Because JAK1/2 sits directly downstream of these cytokines, blocking this pathway is mechanistically well-matched to the disease, distinct from the tenuous "graph co-occurrence" links seen in the other nine PEComa/sarcoma-family predictions (which are mTOR- or SWI/SNF-driven, not JAK-STAT-driven, and have no supporting evidence at all).

This mechanistic plausibility is reinforced by ruxolitinib's approved use in steroid-refractory GvHD — another cytokine-storm-driven inflammatory condition — showing the drug is already used clinically for JAK-STAT-mediated hyperinflammation, not just myeloproliferative disease.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04424056	Phase 3	Unknown	216	Randomized trial of Anakinra/Tocilizumab alone or combined with ruxolitinib for severe COVID-19-associated hyperinflammatory disease (stage 2b/3); status not confirmed as recruiting/completed since last update
NCT07424222	Phase 1	Not yet recruiting	16	Pilot study of ruxolitinib for CAR-T-associated Immune Effector Cell-Associated HLH-like Syndrome (IEC-HS); aims to determine optimal treatment duration and identify response biomarkers

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34605776	2022	Guideline/Consensus	Critical Care Medicine	Consensus guideline on recognition, diagnosis, and management of HLH in critically ill children and adults
35344583	2022	Cohort	Blood	Ruxolitinib as a response-stratified first-line agent in a prospective cohort of pediatric HLH (n=50+)
37787838	2023	Cohort (compassionate use)	Annals of Hematology	Sintilimab + ruxolitinib as compassionate therapy in 12 adults with EBV-associated HLH
40665481	2025	Cohort	British Journal of Haematology	Retrospective comparison: ruxolitinib-based regimen (n=53) vs. adjusted HLH-94 chemotherapy (n=42) in pediatric EBV-HLH
31943120	2020	Review	QJM	Review of adult HLH diagnosis and treatment landscape
31015190	2019	Mechanistic study	Blood	Foundational murine model study establishing ruxolitinib's mechanism of action in HLH (dampens T-cell activation, reduces IFN-γ-driven inflammation)
31879790	2020	Cohort	Annals of Hematology	Ruxolitinib for steroid-refractory acute GvHD in HSCT patients with concurrent EBV-HLH (n=12) — bridges original approved GvHD use and the HLH prediction
38691058	2024	Case Series	J Pediatr Hematol Oncol	Emapalumab + ruxolitinib + dexamethasone for EBV-HLH with multiorgan damage and severe infection
36263041	2022	Case Report	Frontiers in Immunology	Ruxolitinib as first-line therapy for secondary HLH in AIDS patients
37702780	2023	Review	Innere Medizin	Review of HLH management in the ICU setting, including targeted JAK inhibition

New Zealand Market Information

Ruxolitinib currently has no marketed products or authorizations on file in this evidence pack (market status: Not marketed; 0 licenses).

Safety Considerations

Please refer to the package insert for safety information. (No structured warnings, contraindications, or drug-interaction data were available in this evidence pack — this is flagged as a Blocking data gap that must be resolved before any safety assessment.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple cohort studies, a foundational mechanism-of-action study, and case series consistently support ruxolitinib's use in infection/EBV-associated HLH as salvage or first-line therapy, and the JAK-STAT mechanism is directly relevant to this cytokine-storm disease. However, no completed randomized trial yet confirms efficacy (the one Phase 3 trial is status-unknown and the Phase 1 trial hasn't started), and the drug is unmarketed in New Zealand — this keeps the evidence at L3 rather than higher.

To proceed, the following is needed:

Blocking: TFDA/Medsafe package insert (warnings, contraindications) — safety evaluation (S1) cannot proceed without this
Confirmed MOA and DrugBank drug-category data (currently a data gap)
Drug-drug interaction (DDI) data — current query returned no results
Follow-up on NCT04424056 (status UNKNOWN) and NCT07424222 (not yet recruiting) for updated results
A New Zealand regulatory pathway assessment, given zero current local licenses
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.